Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology, reported a significant increase in research and development expenses for the fiscal year ending December 31, 2025. The company incurred approximately $18.2 million in research and development costs, up from $12.9 million in the previous year, reflecting a rise of 42%. General and administrative expenses also rose to about $9.4 million from $6.9 million, marking a 36% increase. The total loss from operations for 2025 was $27.6 million, compared to a loss of $19.8 million in 2024.
The company has not generated any revenue since its inception in July 2020, and it continues to rely on external funding to support its operations. As of December 31, 2025, Nuvectis reported cash and cash equivalents of $31.6 million. The company has raised capital through various offerings, including a public offering in February 2025 that generated approximately $15.5 million in gross proceeds. Nuvectis plans to use these funds to advance the clinical development of its lead product candidate, NXP900, and to support ongoing operational costs.
Nuvectis has made strategic decisions regarding its product pipeline, notably ceasing the clinical development of NXP800 following the completion of a Phase 1b study in July 2025. The company is currently focused on advancing NXP900, which has received Investigational New Drug (IND) clearance from the FDA and is undergoing clinical trials. The ongoing Phase 1b study aims to evaluate the safety and preliminary efficacy of NXP900 in combination with other therapies for specific tumor types.
As of February 6, 2026, Nuvectis employed 13 full-time staff members and has plans to expand its workforce to support its development and commercialization efforts. The company is also navigating the complexities of regulatory compliance and market entry, as it seeks to establish a commercial presence for its product candidates. Nuvectis remains optimistic about its future, emphasizing the importance of securing additional funding to sustain its research and development activities and achieve its long-term goals.
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. Its key products include NXP800, a small molecule targeting ARID1a-mutated ovarian cancer and cholangiocarcinoma, and NXP900, a kinase inhibitor for solid tumors. The company aims to address unmet medical needs in oncology through innovative precision medicines, licensing, and strategic collaborations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.